3 - 5 NOVEMBER 2020 Delivered Digitally VIEW THE AGENDA VIEW THE AGENDA VIEW THE AGENDA 30+ Interactive VIP Access NEW SPEAKERS SESSION PASS FOR IN 2020 FORMATS PHARMA Special Offer for & BIOTECH China Pharmaceutical & Knowledge Partners: Biotech Companies* Brought to you by: www.biopharmaproduction.com CHINA & GLOBAL BIOPHARMA EXPERTS NEW NEW NEW NEW Dr. Song Rulin Liu Xun Zhang Yu Executive President, China Dr. Chris Chen President, Biomedicine President and CEO, Pharmaceutical Innovation and Chief Executive Officer, Development and Business Division, Aeon Therapeutics, China Research Development Association WuXi Biologics, China Jiangsu Hengrui Medicine, China (PhIRDA), China NEW NEW NEW Dr. Orit Aharonovitz Li Jing Rong Lisa Zheng Zhang Zhe Ru Senior Vice President, Product Senior Director, Cell Line & Executive Director, Cell Line President, Head of CMC and Development and Manufacturing, Process Development, Teva Development, Transcenta, China Manufacturing, I-MAB Biopharma, CStone Pharmaceuticals, China Pharmaceuticals, Israel China NEW NEW Dr. Zhu Jianwei NEW NEW Professor and Director of MOE Lynn Yang Yin Nan Po Engineering Research Center of Cell Jerry Su Managing Director, Sequoia Capital, Director, Asia Supply Chain, Amgen, Engineering and Antibody, Shanghai Chief Executive Officer, China China Jiaotong University; CEO and Chief Zhejiang Huahai Biopharmaceuticals Scientist, Jecho Biopharmaceuticals, China NEW NEW NEW NEW John Zhang Dr. Kerstin Otte Yi Jizu Vice President, Manufacturing Professor, Institute of Applied Senior Vice President, CMC & Xi Chen Technology and Process Biotechnology, Biberach University Quality Operations, YZY Biopharma, Director, Cell Engineering, Development, BeiGene, China of Applied Sciences, Germany China Qilu Pharmaceuticals, China NEW NEW NEW NEW Ma Yuan Hui Dr. Jill Cai James Li David Shao Executive Director, Preclinical Vice President, Biologics Bioprocess Co-Founder and CEO, President, Chief Executive Officer, and Development, WuXi Biologics, JW Therapeutics, China Science, Shanghai HaiHe Yisheng Biopharma, China Pharmaceutical, China China NEW Glenn Hassan Wu You Ling Dr. Pan Zhiwei Liu Dong Lian Chief Finance Officer, Chief Business Chief Executive Officer, Senior Director, Process Vice President, Manufacturing, Officer, CANbridge Pharmaceuticals, Zhejiang Teruisi Pharmaceuticals, Development, Junshi Pharma, China TOT BIOPHARM, China China China NEW NEW Frank Ye Rani Jarkas Liang Tang Dr. Song Zhiwei Senior Vice President, Technical Chairman, Cedrus Investments, Vice President, CMC Management, Principal Scientist, Bioprocessing Operations, Transcenta, China Hong Kong WuXi Biologics, China Technology Institute, Singapore NEW NEW NEW Fu Wei Eric Chang Bao Cai Dr. Karen Liu Chief Executive Officer, CBC Group, Head, Cell Line Development, Senior Director, Manufacturing, Founding Partner, 3E Bioventures China JHL Biotech, China Bio-Thera Solutions, China Capital, China www.biopharmaproduction.com CONFERENCE AGENDA DAY 1, TUESDAY 3 NOVEMBER 2020 DAY 2, WEDNESDAY 4 NOVEMBER 2020 DAY 3, THURSDAY 5 NOVEMBER 2020 13.00 Chairperson’s Opening Remarks 16.00 Online Networking & Stretch Break 13.00 Chairperson’s Opening Remarks 15.30 CRISPR in Cell Line Development: 13.00 Chairperson’s Opening Remarks 15.50 Accelerating CLD for Commercial Success Applications of CRISPR in Rapid Development of Stable Dr. Pan Zhiwei, Senior Director, Process Development, JOINT OPENING PLENARY JOINT OPENING PLENARY 16.20 Efficient Cell Lines and Technology Applications JOINT OPENING PLENARY Transgene CHO Cell Lines Junshi Pharma, China Joint Plenary Sessions with 10th Annual Biomanufacturing and Joint Plenary Sessions with 10th Annual Biomanufacturing and Joint Plenary Sessions with 10th Annual Biomanufacturing and Lisa Zheng, Executive Director, Cell Line Development, Dr. Zhu Jianwei, Professor and Director of MOE 2nd Annual Cell & Gene Therapy Manufacturing 2nd Annual Cell & Gene Therapy Manufacturing 16.20 Online Networking & Stretch Break 2nd Annual Cell & Gene Therapy Manufacturing Transcenta, China Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief 13.10 Manufacturers’ Panel: 13.10 KEYNOTE ADDRESS 13.10 KEYNOTE ADDRESS Scientist, Jecho Biopharmaceuticals, China 16.40 Using CHO to Develop Biosimilars from Non-CHO Host 16.50 Developing a New CLD Process from Ground-Up New Therapies, New Tech and New Investments China’s Biopharma Capital Markets – Future Funds and Cell Line China’s Big Leap Towards BioPharma 2030 – Innovation, • Navigating the complex landscape of strategies for • New frontiers in drug development Innovative Financing 16.00 Online Networking & Stretch Break Eric Chang, Head, Cell Line Development, JHL Biotech, Industrialization, Internationalization generating new cell lines • What is the gap in quality and investment? Fu Wei, Chief Executive Officer, CBC Group, China China Dr. Song Ru Lin, Executive President, China • Embracing new tech and start-ups to drive progress • From DNA to lead clones, what new technologies 16.20 Advances in Single-Cell Genomics and RNA Sequencing Pharmaceutical Innovation and Research Development • New therapeutics manufacturing, commercialisation 13.40 Venture Capitals Roundtable: and core instrumentation may impact future protein Tools for Effective CLD* 17.10 A Fully Integrated Platform Approach for Highly-Quality Association (PhIRDA), China and global access Show Me the Drug CLD expression and cell line development campaigns? Session Reserved for Namocell • Biomanufacturing 4.0 – Where are we at? • Investment landscape of Chinese biopharma market • Case study in Henlius’ in-house capabilities across Mark Stockdale, Amalgamator of Business and Biology, • DAL’s GAMP and licensing laws – How is it affecting • Evaluating drug pipelines and development prospects the entire biologics value chain spanning across: 13.40 KEYNOTE ADDRESS Solentim, U.K. 16.50 Next-Generation Cell Line Engineering for our business and what we can expect? • Mergers, expansion and JVs – Where do we see - High-titer cell lines; China’s Biological Facilities for the Future – WuXi’s Story Biopharmaceutical Production • The GQCE framework – quality consistency and transactions picking up? - Proprietary cell culture production; and on Technology and Innovation • Advancing microRNA to optimize and boost 17.20 High-Throughput Cloning Screening and Performance better pricing • Financing new plants, new therapeutics, product - Continuous manufacturing process for commercial Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, for Next-Generation Innovative Therapeutics productivity of cell line growth launch and scaling-up operations – How do we production Panelists: China Ting Chen, Director, Alphamab Oncology, China • Use cases and applications of CRISPR/Cas9- review? Senior Representative from Shanghai Henlius Biotech, Jerry Su, Chief Executive Officer, Zhejiang Huahai mediated knockout for enhanced titre • Manufacturing 4.0 – How do VCs and banks play a China 14.10 Online Networking & Stretch Break Biopharmaceuticals, China • Identifying bottlenecks in CLD: a streamlined and part in modernising the value chain? 17.50 Expanding Beyond Traditional Monoclonal Antibodies in Glenn Hassan, Chief Finance Officer, Chief Business high-throughput approach 17.40 Panel Discussion: What’s Next in the Future of CLD&E Cell Line Development Officer, CANbridge Pharmaceuticals, China (tentatively th Dr. Kerstin Otte, Professor, Institute of Applied Panelists: • What is the next thing in medicine that we will need to 9 Annual Cell Line Development & Engineering Asia • Use case for the generation of the highest titer confirming) Biotechnology, Biberach University of Applied Sciences, Rani Jarkas, Chairman, Cedrus Investments, Hong Kong produce? Commences William Cao, Founder, Chairman & CEO, Gracell production cell lines in under 1 week Germany Judith Li, Partner, Lilly Asia Ventures, China • Biotechnologies Group, China A look ATMPs, tissue generation, stem cells, • A look at how pharma is moving cell line development Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, exosomes and more 14.20 Chairperson’s Opening Remarks earlier in the therapeutic development timeline 17.20 Applications for Glycan Analysis Workflows and China 14.00 Online Networking & Stretch Break • The landscape for CRISPR: how ready or willing is the Dr. Orit Aharonovitz, Senior Director, Cell Line & Process • Delivering >99% monoclonality with every campaign Bioanalytical Proteins* Lynn Yang, Managing Director, Sequoia Capital, China industry to use CRISPR for cell line engineering? Development, Teva Pharmaceuticals, Israel Dr. John Zhu, Partner, 6 Dimensions Capital, China through optimizing your CLD workflow 9th Annual Cell Line Development & Engineering Asia Senior Representative from ProZyme • Partnerships and ventures for furthering biopharma Dr. John Proctor, Senior Vice President, Marketing, R&D capabilities and strategies Resumes 14.20 Online Networking & Stretch Break THE STATE-OF-PLAY FOR CLD Berkeley Lights, U.S. 17.50 Industry Panel: Utilising Platform Technologies for CLD 14.20 Chairperson’s Opening Remarks • Navigating the systems and various methods to Moderator: 9 th Annual Cell Line Development & Engineering Asia 14.30 OPENING KEYNOTE accomplish their goals; comparing and contrasting Dr. Song Zhiwei, Principal Scientist, Bioprocessing 18.20 End of Conference Day 1 Resumes Optimising Cell Line Development: Applications for ENGINEERING HOST CELL LINES, GENOMICS tools Technology Institute,